SAB2500398
Anti-FHL2 antibody produced in goat
affinity isolated antibody, buffered aqueous solution
Sinónimos:
Anti-AAG11, Anti-DRAL, Anti-Down-regulated in rhabdomyosarcoma LIM protein, Anti-SLIM3
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA (i), WB
Citations:
1
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlebiological source
goat
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
mouse, human, rat
technique(s)
indirect ELISA: suitable, western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... FHL2(2274)
Immunogen
Peptide with sequence RDDILCPDCGKDI from the C Terminus of the protein sequence according to NP_001441.4; NP_963849.1; NP_963851.2; NP_001034581.1.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.
Still not finding the right product?
Pruebe nuestra Herramienta de selección de productos para limitar sus opciones
signalword
Warning
hcodes
pcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Clase de almacenamiento
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Xiaoping Yi et al.
Oncology letters, 14(4), 4883-4889 (2017-09-26)
Pancreatic cancer (PC) is one of the most aggressive types of cancer with an extremely poor prognosis. Invasive growth and early metastasis is one of the greatest challenges to overcome for the treatment of PC. Numerous previous studies have indicated